Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 4, 1998, Pages 511-518

  Biron, Pierre ^a   Fuhrmann, Christine ^a   Cure, Hervé ^b   Viens, Patrice ^c   Lefebvre, Danièle ^d   Thyss, Antoine ^e   Viot, Michèle ^e   Soler Michel, Patricia ^f   Rollin, Christian ^g   Grès, Jean Jacques ^g  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE JEAN PERRIN   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f RCTs   (France)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM;

ARTICLE; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VOMITING;

ANTINEOPLASTIC AGENTS; CEPHALOSPORINS; CILASTATIN; DRUG THERAPY, COMBINATION; FEVER; HUMANS; IMIPENEM; NEOPLASMS; NEUTROPENIA; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0031667545     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.4.511     Document Type: Article

References (19)

1. Bodey, G. P., Buckley, M., Sathe, Y. S. & Freireich, E. J. (1966). Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. Annals of Internal Medicine 64, 328-40.
2. Hughes, W. T., Armstrong, D., Bodey, G. P., Feld, R., Mandell, G. L., Meyers, J. D. et al. (1990). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161, 381-96.
3. Pizzo, P. A., Armstrong, D., Bodey, G., De Pauw, B., Feld, R., Glauser, M. et al. (1990). The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of consensus panel. Journal of Infectious Diseases 161, 397-401.
4. Hughes, W. T., Pizzo, P. A., Wade, J. C., Armstrong, D., Webb, C. D. & Young, L. S. (1993). General guidelines for the evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. In European Guidelines for the Clinical Evaluation of Anti-Infective Drug Products (ESCMID), pp. 221-7.
5. Pizzo, P. A. (1993). Management of fever in patients with cancer and treatment-induced neutropenia. New England Journal of Medicine 328, 1323-32.
6. Biron, P., Fuhrmann, C. & Viot, M. for the CEMIC. (1995). Neutropénies: résultats préliminaires avec le céfépime 2g/j × 2. La Lettre de l'Infectiologue, Suppl., 11-2.
7. Sanders, J. W., Powe, N. R. & Moore, R. D. (1991). Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. Journal of Infectious Diseases 164, 907-16.
8. Rolston, K. V., Berkey, P., Bodey, G. P., Annaissie, E. J., Khardori, N. M., Joshi, J. H. et al. (1992). A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine 152, 283-91.
9. Freifeld, A. G., Walsh, T., Marshall, D., Gress, J., Steinberg, S. M., Hathorn, J. et al. (1995). Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. Journal of Clinical Oncology 13, 165-76.
10. The Meropenem Study Group of Leuven, London and Nijmegen. (1995). Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 36, 185-200.
11. Cometta, A., Calandra, T., Gaya, H., Zinner, S. H., de Bock, R., Del Favero, A. et al. (1996). Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 40, 1108-15.
12. Bodey, G., Abi-Said, D., Rolston, K., Raad, I. & Whimbey, E. (1996). Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. European Journal of Clinical Microbiology and Infectious Diseases 15, 625-34.
13. Barradell, L. B. & Bryson, H. M. (1994). Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 47, 471-505.
14. Fung-Tomc, J., Dougherty, T. J., DeOrio, F. J., Simich-Jacobson, V. & Kessler, R. E. (1989). Activity of cefepime against ceftazidime and cefotaxime resistant Gram-negative bacteria and its relationship to β-lactamase levels. Antimicrobial Agents and Chemotherapy 33, 498-502.
15. Eggimann, P., Glauser, M. P., Aoun, M., Meunier, F. & Calandra, T. (1993). Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. Journal of Antimicrobial Chemotherapy 32, Suppl. B, 151-63.
16. Cordonnier, C., Herbrecht, R., Pico, J. L., Gardembas, M., Delmer, A., Delain, M. et al. (1997). Cefepime-amikacin versus ceftazidime-amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clinical Infectious Diseases 24, 41-51.
17. Glauser, M. P. (1995). Clinical results with cefepime in cancer patients with fever and neutropenia. Canadian Journal of Infectious Diseases 6, Suppl. C, 202C [abstract 80].
18. Ramphal, R., Gucalp, R., Rotstein, C., Cimino, M. & Oblon, D. (1996). Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. American Journal of Medicine 100, Suppl. 6A, 83S-89S.
19. Rodary, C., Com-Nougue, C. & Tournade, M. F. (1989). How to establish equivalence between treatments: a one-sided clinical trial in paediatric oncology. Statistics in Medicine 8, 593-8.